17¦Á Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth

详细信息    查看全文

• 作者：Paul Merlob^a ; ^b ; ^c ; Bracha Stahl^a ; Gil Klinger^a ; ^b ; ^c ; ^{gilkl@post.tau.ac.il}
• 关键词：17-OHP ; 17-hydroxyprogesterone ; 17-OHPC ; 17-alpha-hydroxyprogesterone caproate ; SRPB ; spontaneous recurrent preterm birth ; CAP ; contraction-associated protein ; CNX43 ; connexin 43 ; OXTR ; oxytocin-receptor
• 刊名：Reproductive Toxicology
• 出版年：2012
• 出版时间：January 2012
• 年：2012
• 卷：33
• 期：1
• 页码：15-19
• 全文大小：458 K

文摘

Use of 17-alpha-hydroxyprogesterone caproate for the prevention of spontaneous preterm birth in women at risk is reviewed. Early studies regarding this topic reached contradicting conclusions, however recent studies showed that weekly injections of 17-alpha-hydroxyprogesterone caproate beginning at 16-20 weeks?gestation resulted in a substantial reduction in the rate of spontaneous recurrent preterm birth. Long-term follow-up of children exposed in-utero to the drug has shown normal growth and development and normal scores for gender specific roles. In conclusion, 17-alpha-hydroxyprogesterone caproate is currently the only drug with sufficient evidence to support its use for prevention of spontaneous recurrent preterm birth.